Explore
Validate
Learn
Western blot
ImmunohistochemistryAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Immunohistochemistry [2]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-40946 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- TRIM15 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Peptide sequence: RDEIEDVKCQ EDQKLQVLLT QIESKKHQVE TAFERLQQEL EQQRCLLLAR Sequence homology: Cow: 86%; Horse: 86%; Human: 100%; Mouse: 93%; Rabbit: 79%; Rat: 86%
- Reactivity
- Human
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 1 mg/mL
- Storage
- -20°C, Avoid Freeze/Thaw Cycles
Submitted references E3 ligase TRIM15 facilitates non-small cell lung cancer progression through mediating Keap1-Nrf2 signaling pathway.
Liang M, Wang L, Sun Z, Chen X, Wang H, Qin L, Zhao W, Geng B
Cell communication and signaling : CCS 2022 May 9;20(1):62
Cell communication and signaling : CCS 2022 May 9;20(1):62
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of human intestine tissue using an anti-TRIM15 polyclonal antibody (Product # PA5-40946).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of human kidney tissue using an anti-TRIM15 polyclonal antibody (Product # PA5-40946).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 1 TRIM15 is upregulated in NSCLC and associated with NSCLC progression. A The gene expression of TRIM15 between NSCLC samples and normal lung tissue from GEPIA. LUAD (Lung adenocarcinoma), LUSC (Lung squamous cell carcinoma). B Western blot analysis of TRIM15 expression in NSCLC tissues compared with corresponding noncancerous lung tissues. C IHC analysis of TRIM15 expression in 2 NSCLC samples. Representative images are shown. Scale bar, 100 mum. D Representative IHC images of TRIM15 in NSCLC tissues with or without distant metastasis. Scale bar, 200 mum. E OS analysis of patients with NSCLC stratified by the TRIM15 expression level in 98 samples. Patients with high-expression levels of TRIM15 had shorter OS times than patients with low expression levels. ** P < 0.01
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Roles of TRIM15 in promoting NSCLC growth and metastasis. A Expression levels of TRIM15 in the indicated lung cancer cell lines were analysed by western blotting. Confirmation of TRIM15 knockdown in H1299. H1650 cells were transfected with control plasmids or vector expressing TRIM15 or TRIM15-DeltaRING. Immunoblot detection of TRIM15 and TRIM15-DeltaRING expression in H1650 cells. B , C The effect of TRIM15 knockdown and overexpression on NSCLC cells proliferation was assessed by CCK8 and EdU-incorporation assay. D , E The effects of TRIM15 loss- or gain-of-function on migration ( D ) and invasion ( E ) of NSCLC cells. Knockdown of TRIM15 resulted in significant inhibited migration ( D ) and invasion ( E ) of H1299 cells. TRIM15 upregulation significantly increased cancer cell migration ( D ) and invasion ( E ), while the TRIM15-DeltaRING lost this ability. Statistical analyses were performed by two-tailed unpaired Student's t -test. ** P < 0.01
